Homologous sequence targeting in eukaryotic cells

• US 6,255,113 B1
• Filed: 02/08/1995
• Issued: 07/03/2001
• Est. Priority Date: 04/24/1992
• Status: Expired due to Term

• Current Assignee: SRI International, Inc.
• Original Assignee: SRI International, Inc.
• Inventors: Zarling, David A., Sena, Elissa P.
• Primary Examiner(s): Chambers, Jasemine
• Assistant Examiner(s): Martin, Jill D.
• Application Number:
  US08/385,713
• Time in Patent Office: 2,337 Days
• Field of Search: 435/172.1, 435/172.3, 435/320.1, 435/240.1, 435/240.2, 435/240.21, 435/463, 435/462, 435/455, 435/461, 435/458, 435/465, 435/325, 514/44, 424/93.21, 800/25
• US Class Current: 435/463
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/4712 Cystic fibrosis
• CPC Class Codes: C07K 14/82 Translation products from oncogenes
• CPC Class Codes: C12N 15/907 in mammalian cells

Abstract

The invention relates to methods for targeting an exogenous polynucleotide or exogenous complementary polynucleotide pair to a predetermined endogenous DNA target sequence in a eukaryotic cell by homologous pairing, particularly for altering an endogenous DNA sequence, such as a chromosomal DNA sequence, typically by targeted homologous recombination. In certain embodiments, the invention relates to methods for targeting an exogenous polynucleotide having a linked chemical substituent to a predetermined endogenous DNA sequence in a metabolically active eukaryotic cell, generating a DNA sequence-specific targeting of one or more chemical substituents in an intact nucleus of a metabolically active eukaryotic cell, generally for purposes of altering a predetermined endogenous DNA sequence in the cell. The invention also relates to compositions that contain exogenous targeting polynucleotides, complementary pairs of exogenous targeting polynucleotides, chemical substituents of such polynucleotides, and recombinase proteins used in the methods of the invention.

Claims

1. A method for targeting and altering, by homologous recombination, a preselected target DNA sequence in a eukaryotic cell in vitro to make a targeted sequence modification, said method comprising:

introducing into at least one eukaryotic cell at least one recombinase and at least two single-stranded targeting polynucleotides which are substantially complementary to each other, and which further comprise a homology clamp that substantially corresponds to or is substantially complementary to said preselected target DNA sequence and;

identifying a eukaryotic cell having a the at a preselected target DNA sequence.

2. A method according to claim 1, wherein said recombinase is a recA recombinase.

3. A method according to claim 2, wherein said recA recombinase is E. coli recA recombinase.

4. A method according to claim 1, wherein at least one of said targeting polynucleotides is conjugated by non-covalent binding to a cell-uptake component.

5. A method according to claim 4, wherein said cell-uptake component is conjugated to said at least one targeting polynucleotides by noncovalent binding to a poly-L-lysine conjugate or a cationic lipid.

6. A method according to claim 4, wherein the cell-uptake component comprises poly-L-lysine conjugated to an asialoglycoprotein.

7. A method according to claim 4, wherein said at least one targeting polynucleotides is non-covalently conjugated to a cell-uptake component and to a recombinase, forming a cell targeting complex.

8. A method according to claim 1, wherein said targeting polynucleotides form a double-stranded nucleic acid.

9. A method according to claim 1, wherein the targeted sequence modification comprises a deletion of at least one nucleotide from said preselected target DNA sequence in said eukaryotic cell.

10. A method according to claim 1, wherein the targeted sequence modification comprises the addition of at least one nucleotide to said preselected target DNA sequence in said eukaryotic cell.

11. A method according to claim 1, wherein the recombinase and said targeting polynucleotides are introduced into the eukaryotic cell simultaneously.

12. A method according to claim 11, wherein the recombinase and the targeting polynucleotides are introduced into the eukaryotic cell by microinjection, electroporation, and contacting the cell with a lipid-protein-targeting polynucleotide complex that facilitates entry into said eukaryotic cell.

13. A method according to claim 1, wherein said identifying of the targeted cell is accomplished by detection of the targeted DNA sequence modification by Southern blot, PCR detection, or phenotype selection.

14. A method according to claim 13, wherein said phenotype selection comprises selection for cells expressing a neo or HSV-tk drug-resistance gene.

15. A method according to claim 1, wherein the targeted sequence modification comprises the substitution of at least one nucleotide for at least one nucleotide in said preselected target DNA sequence in said eukaryotic cell.

16. A method for generating a targeted sequence modification in a preselected endogenous target DNA sequence in a eukaryotic cell in vitro, comprising:

introducing into a eukaryotic cell, a recombinase having strand transfer activity and at least two single-stranded targeting polynucleotides which are substantially complementary to each other, and which further comprise a homology clamp that substantially corresponds to or is substantially complementary to said preselected endogenous target DNA sequence; and

identifying a eukaryotic cell having the targeted sequence modification at said preselected endogenous target DNA sequence.

17. A method according to claim 16, wherein said identifying of the targeted cell is accomplished by detection of the targeted DNA sequence modification by Southern blot, PCR detection or phenotype selection.

18. A method according to claim 17, wherein said phenotype selection comprises selection for cells expressing a neo or HSV-tk drug-resistance gene.

19. A method according to claim 16, wherein the recombinase having strand transfer activity is selected from the group consisting of:

recA, recA803, uvsX, and rec1.

20. A method for targeting and altering, by homologous recombination, a preselected DNA sequence in a eukaryotic cell in vitro to make a targeted sequence modification, said method comprising introducing into at least one eukaryotic cell at least one recA recombinase and at least two single-stranded targeting polynucleotides which are substantially complementary to each other, and which further comprise a homology clamp that substantially corresponds to or is substantially complementary to a preselected target DNA sequence;

and identifying a eukaryotic cell having the targetet DNA sequence modification at a preselected target DNA sequence.